Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong Li, Ph.D., M.B.A. as Senior Vice President of Corporate Development.
EMERYVILLE, California, February 7, 2019 –Eureka Therapeutics Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong Li, Ph.D., M.B.A. as Senior Vice President of Corporate Development.
“It is my pleasure to welcome Hanzhong to Eureka,” said Cheng Liu, Ph.D., President and Chief Executive Officer of Eureka. “Hanzhong is an industry expert with a rare blend of insights into the biotech industry and deep relationships within the financial community. We are very fortunate to have him join the Eureka team and look forward to working with him at the inflection point of the Company’s transformation and growth.”
Dr. Li has over twenty years of combined experience in finance and the biopharmaceutical industries. Prior to joining Eureka, Dr. Li was the Chief Financial Officer of the Ascentage Pharma Group. From 2010 to 2017, Dr. Li had worked in the Strategy and Portfolio Management Group as a Deputy Director at Bayer Pharmaceuticals. Before Bayer, Dr. Li was a Biotech Analyst at Morgan Stanley, Suntrust Robinson Humphrey, and Stanford Financial Group, covering biotech industry. Prior to that, Dr. Li was a Research Scientist at Genentech in drug discovery and was a lead inventor of three international patents on novel cytokines. Dr. Li holds a Ph.D. degree in Pharmacology from Boston University School of Medicine and an M.B.A. degree in Finance from University of California at Los Angeles.
“I’ve watched and been greatly impressed by the transformative technology at Eureka. The early results from Eureka’s first-in-human study of ET140202 ARTEMIS T-cell therapy for hepatocellular carcinoma (HCC) is very promising,” said Dr. Li. “I am excited about the opportunity to make contributions to Eureka’s growth and to make a difference in the lives of cancer patients.”
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company developing antibody-TCR (AbTCR) T-Cell Therapies for solid and hematological malignancies. Its core technology centers around its proprietary ARTEMIS™ AbTCR T-cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of multiple solid and hematologic tumors.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.
CONTACTS:
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-722-8720
